
Claims:

1. A pharmaceutical composition comprising

a) a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof,



(I)

b) one or more, e.g. 1, 2 or 3, surfactants with lubricant properties;

c) one or more, e.g. 1, 2 or 3, dry binders with disintegrant properties;

d) one or more, e.g. 1, 2 or 3, fillers, and

e) one or more, e.g. 1, 2 or 3, disintegrants.

2. The pharmaceutical composition according to claim 1, further comprising one or more, e.g. 1, 2 or 3, lubricants.

3. The pharmaceutical composition according to any one of the preceding claims, wherein the surfactant is selected from sodium lauryl sulfate, stearic acid, palmitic acid, myristic acid, poloxamers and polyethylene glycols such as PEG 4000-8000, Tween series of surfactants, Brij series of surfactants (i.e., Brij 80), Triton X-100, and combinations thereof.

4. The pharmaceutical composition according to any one of the preceding claims, wherein the surfactant is present in an amount which is 0.1 to 5% by weight of the composition.

5. The pharmaceutical composition according to any one of the preceding claims, wherein the dry binder is selected from polyethylene glycols (PEG), e.g., PEG 4000; pregelatinized starch; starch; chitosan; guar gum, microcrystalline cellulose; methyl cellulose; calcium carboxymethylcellulose; sodium carboxymethylcellulose, alginic acid and/or its sodium salt; hydroxypropylmethyl cellulose or hydroxypropyl cellulose, both preferably of medium to high viscosity, e.g., viscosity grades 3 or 6 cps, e.g. low substituted hydroxypropyl cellulose (L-HPC LH-21); and combinations thereof.

6. The pharmaceutical composition according to any one of the preceding claims, wherein the dry binder is present in an amount which is 5 to 15% by weight of the composition.

7. The pharmaceutical composition according to any one of the preceding claims, wherein the filler is microcrystalline cellulose, Anhydrous Dicalcium Phosphate and Anhydrous Lactose , or a mixture thereof.

8. The pharmaceutical composition according to any one of the preceding claims, wherein the filler is a mixture of Anhydrous Lactose and microcrystalline cellulose wherein the ratio of microcrystalline cellulose and Anhydrous Lactose actose is between 1:5 and 1:1.

9. The pharmaceutical composition according to any one of the preceding claims, wherein the disintegrant is crosscarmellose sodium, cross-linked polyvinyl pyrrolidone, Sodium Starch Glycollate.

10. The pharmaceutical composition according to any one of the preceding claims, wherein the disintegrant is present in an amount which is 2-10% by weight of the tablet.

11. The pharmaceutical composition according to any one of the preceding claims, wherein the disintegrant is present in an amount which is 2, 6 or 9% by weight of the tablet.

12. The pharmaceutical composition according to any one of the preceding claims, wherein the salt of the compound of formula (I) is the sodium salt.

13. The pharmaceutical composition according to any of the preceding claims in the form of a tablet.

14. A method for treating or preventing a condition or disorder associated with DGAT1 activity, comprising administering to an animal, including a human patient, in need of such treatment a therapeutically effective amount of a pharmaceutical composition according to any one of the preceding claims..

15. A pharmaceutical composition according to any one of the preceding claims for use in treating or preventing a condition or disorder associated with DGAT1 activity.

16. A process for preparing a pharmaceutical composition according to any one of the preceding claims comprising the steps of:

(a) mixing the compound of the formula (I), or a pharmaceutically acceptable salt thereof with at least one pharmaceutically acceptable excipient to form a blend;

(b) roller compacting, then milling said blend;


(c) lubricating the resulting mixture, and

(d) compressing the resulting mixture into a solid oral dosage form.

Claims:

1. A pharmaceutical composition in the form of a tablet comprising

a) a therapeutically effective amount of the sodium salt of a compound of formula (I)



(I)

b) one or more, e.g. 1, 2 or 3, surfactants with lubricant properties, wherein said surfactant is sodium lauryl sulfate, stearic acid, palmitic acid, myristic acid, poloxamers and polyethylene glycols such as PEG 4000-8000, Tween series of surfactants, Brij series of surfactants, Triton X-100, or a combination thereof, and
wherein the surfactant is present in an amount which is 0.1 to 5% by weight of the tablet prior to any film coating;

c) one or more, e.g. 1, 2 or 3, dry binders with disintegrant properties, wherein said dry binder is polyethylene glycols (PEG); pregelatinized starch; starch; chitosan; guar gum, microcrystalline cellulose; methyl cellulose; calcium carboxymethylcellulose; sodium carboxymethylcellulose, alginic acid and/or its sodium salt; hydroxypropylmethyl cellulose or hydroxypropyl cellulose, or a combination thereof, and
wherein the dry binder is present in an amount which is 2 to 20% by weight of the tablet prior to any film coating;

d) one or more, e.g. 1, 2 or 3, fillers, wherein said filler is microcrystalline cellulose, low-substituted hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, Anhydrous Dicalcium Phosphate, Dicalcium Phosphate, lactose, Anhydrous Lactose, or a combination thereof, and

wherein the filler is present in an amount which is 4% to 85% by weight of the tablet prior to any film coating, and

e) one or more, e.g. 1, 2 or 3, disintegrants, wherein the disintegrant is carboxymethylcellulose calcium (CMC-Ca), carboxymethylcellulose sodium (CMC-Na), crosscarmellose sodium, cross-linked polyvinyl pyrrolidone, Sodium Starch Glycollate; alginic acid, sodium alginate, guar gum or a combination thereof; and
wherein the disintegrant is present in an amount which is 1 to 10% by weight of the tablet prior to any film coating.

2. The pharmaceutical composition according to claim 1, further comprising one or more, e.g. 1, 2 or 3, lubricants, wherein the lubricant is magnesium stearate, aluminum silicate, calcium silicate, stearic acid, cutina, PEG 4000-8000, talc or a combination thereof, and wherein the lubricant is present in an amount which is from 0.1% to 10% by weight of the tablet prior to any film coating.

3. The pharmaceutical composition according to any one of the preceding claims, further comprising a glidant, wherein the glidant is colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc or a combination thereof, and
wherein the glidant is present in an amount ranging from 0.05% to 5% by weight of the tablet prior to any film coating.

4. The pharmaceutical composition according to any one of the preceding claims, wherein the surfactant is sodium lauryl sulfate.

5. The pharmaceutical composition according to any one of the preceding claims, wherein the dry binder is hydroxypropylmethyl cellulose, hydroxypropyl cellulose or combinations thereof.

6. The pharmaceutical composition according to claim 5, wherein the hydroxypropylmethyl cellulose or hydroxypropyl cellulose is of medium to high viscosity.

7. The pharmaceutical composition according to claim 5, wherein the hydroxypropylmethyl cellulose or hydroxypropyl cellulose is of viscosity grades 3 or 6 cps.

8. The pharmaceutical composition according to claim 5, wherein the hydroxypropyl cellulose is low substituted hydroxypropyl cellulose (L-HPC LH-21).

9. The pharmaceutical composition according to any one of the preceding claims, wherein the dry binder is present in an amount which is 5 to 15% by weight of the composition.

10. The pharmaceutical composition according to any one of the preceding claims, wherein the filler is microcrystalline cellulose, Anhydrous Dicalcium Phosphate, Anhydrous Lactose, or a mixture thereof.

11. The pharmaceutical composition according to any one of the preceding claims, wherein the filler is a mixture of Anhydrous Lactose and microcrystalline cellulose wherein the ratio of microcrystalline cellulose and Anhydrous Lactose is between 1:5 and 1:1.

12. The pharmaceutical composition according to claim 11, wherein the ratio of microcrystalline cellulose and Anhydrous Lactose is 1:2.

13. The pharmaceutical composition according to any one of the preceding claims, wherein the disintegrant is crosscarmellose sodium, cross-linked polyvinyl pyrrolidone, or Sodium Starch Glycollate.

14. The pharmaceutical composition according to claim 13, wherein the disintegrant is Sodium Starch Glycollate.

15. The pharmaceutical composition according to any one of the preceding claims, wherein the disintegrant is present in an amount which is 2, 6 or 9% by weight of the tablet, prior to any optional film coating and based on the free acid of the compound of formula (I).

16. The pharmaceutical composition according to any one of the preceding claims, wherein the compound of formula (I) is present in an amount ranging from about 0.1% to about 50% by weight of the tablet prior to any optional film coating and based on the free acid of the compound of formula (I).

17. The pharmaceutical composition according to claim 16, wherein the compound of formula (I) is present in an amount ranging from about 0.5% to about 30% by

weight of the tablet prior to any optional film coating and based on the free acid of the compound of formula (I).

18. The pharmaceutical composition according to claim 16, wherein the compound of formula (I) is present in an amount ranging from about 1% to about 30% by weight of the tablet prior to any optional film coating and based on the free acid of the compound of formula (I).

19. The pharmaceutical composition according to any one of the preceding claims, wherein the surfactant is sodium lauryl sulfate;
the dry binder is low substituted hydroxypropyl cellulose (L-HPC LH-21);
the filer is a mixture of Anhydrous Lactose and microcrystalline cellulose wherein the ratio of microcrystalline cellulose and Anhydrous Lactose is between 1:5 and 1:1; and
the disintegrant is Sodium Starch Glycollate.

20. The pharmaceutical composition according to claim 19, wherein the ratio of microcrystalline cellulose and Anhydrous Lactose is 1:2.

21. The pharmaceutical composition according to any one of claims 2 to 20, wherein the lubricant is Sodium Stearyl Fumarate.

22. A process for preparing a pharmaceutical composition according to any one of claims 1 to 21 comprising the steps of:

(a) mixing the sodium salt of the compound of formula (I) with at least one pharmaceutically acceptable excipient to form a blend;

(b) roller compacting, then milling said blend;

(c) lubricating the resulting mixture; and

(d) compressing the resulting mixture into a solid oral dosage form.

23. Use of the pharmaceutical composition according to any one of claims 1 to 21 in the manufacture of a medicament for the treatment or prevention of a condition or disorder associated with DGAT1 activity.